Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Identifieur interne : 000535 ( PubMed/Corpus ); précédent : 000534; suivant : 000536Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
Auteurs : David Devos ; Caroline Moreau ; Jean Christophe Devedjian ; Jérome Kluza ; Maud Petrault ; Charlotte Laloux ; Aurélie Jonneaux ; Gilles Ryckewaert ; Guillaume Garçon ; Nathalie Rouaix ; Alain Duhamel ; Patrice Jissendi ; Kathy Dujardin ; Florent Auger ; Laura Ravasi ; Lucie Hopes ; Guillaume Grolez ; Wance Firdaus ; Bernard Sablonnière ; Isabelle Strubi-Vuillaume ; Noel Zahr ; Alain Destée ; Jean-Christophe Corvol ; Dominik Pöltl ; Marcel Leist ; Christian Rose ; Luc Defebvre ; Philippe Marchetti ; Z Ioav Cabantchik ; Régis BordetSource :
- Antioxidants & redox signaling [ 1557-7716 ] ; 2014.
English descriptors
- KwdEn :
- Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Iron (metabolism), Iron Chelating Agents (administration & dosage), Iron Chelating Agents (therapeutic use), Male, Mice, Mice, Inbred C57BL, Motor Activity (drug effects), Oxidative Stress (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Pilot Projects, Pyridones (administration & dosage), Pyridones (pharmacology), Pyridones (therapeutic use).
- MESH :
- chemical , administration & dosage : Iron Chelating Agents, Pyridones.
- chemical , metabolism : Iron.
- chemical , pharmacology : Pyridones.
- chemical , therapeutic use : Iron Chelating Agents, Pyridones.
- drug effects : Motor Activity, Oxidative Stress.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- Animals, Cell Line, Combined Modality Therapy, Disease Models, Animal, Double-Blind Method, Humans, Male, Mice, Mice, Inbred C57BL, Pilot Projects.
Abstract
The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments.
DOI: 10.1089/ars.2013.5593
PubMed: 24251381
Links to Exploration step
pubmed:24251381Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting chelatable iron as a therapeutic modality in Parkinson's disease.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><nlm:affiliation>1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University , CHU Lille, Lille, France .</nlm:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name></author><author><name sortKey="Devedjian, Jean Christophe" sort="Devedjian, Jean Christophe" uniqKey="Devedjian J" first="Jean Christophe" last="Devedjian">Jean Christophe Devedjian</name></author><author><name sortKey="Kluza, Jerome" sort="Kluza, Jerome" uniqKey="Kluza J" first="Jérome" last="Kluza">Jérome Kluza</name></author><author><name sortKey="Petrault, Maud" sort="Petrault, Maud" uniqKey="Petrault M" first="Maud" last="Petrault">Maud Petrault</name></author><author><name sortKey="Laloux, Charlotte" sort="Laloux, Charlotte" uniqKey="Laloux C" first="Charlotte" last="Laloux">Charlotte Laloux</name></author><author><name sortKey="Jonneaux, Aurelie" sort="Jonneaux, Aurelie" uniqKey="Jonneaux A" first="Aurélie" last="Jonneaux">Aurélie Jonneaux</name></author><author><name sortKey="Ryckewaert, Gilles" sort="Ryckewaert, Gilles" uniqKey="Ryckewaert G" first="Gilles" last="Ryckewaert">Gilles Ryckewaert</name></author><author><name sortKey="Garcon, Guillaume" sort="Garcon, Guillaume" uniqKey="Garcon G" first="Guillaume" last="Garçon">Guillaume Garçon</name></author><author><name sortKey="Rouaix, Nathalie" sort="Rouaix, Nathalie" uniqKey="Rouaix N" first="Nathalie" last="Rouaix">Nathalie Rouaix</name></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name></author><author><name sortKey="Jissendi, Patrice" sort="Jissendi, Patrice" uniqKey="Jissendi P" first="Patrice" last="Jissendi">Patrice Jissendi</name></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Auger, Florent" sort="Auger, Florent" uniqKey="Auger F" first="Florent" last="Auger">Florent Auger</name></author><author><name sortKey="Ravasi, Laura" sort="Ravasi, Laura" uniqKey="Ravasi L" first="Laura" last="Ravasi">Laura Ravasi</name></author><author><name sortKey="Hopes, Lucie" sort="Hopes, Lucie" uniqKey="Hopes L" first="Lucie" last="Hopes">Lucie Hopes</name></author><author><name sortKey="Grolez, Guillaume" sort="Grolez, Guillaume" uniqKey="Grolez G" first="Guillaume" last="Grolez">Guillaume Grolez</name></author><author><name sortKey="Firdaus, Wance" sort="Firdaus, Wance" uniqKey="Firdaus W" first="Wance" last="Firdaus">Wance Firdaus</name></author><author><name sortKey="Sablonniere, Bernard" sort="Sablonniere, Bernard" uniqKey="Sablonniere B" first="Bernard" last="Sablonnière">Bernard Sablonnière</name></author><author><name sortKey="Strubi Vuillaume, Isabelle" sort="Strubi Vuillaume, Isabelle" uniqKey="Strubi Vuillaume I" first="Isabelle" last="Strubi-Vuillaume">Isabelle Strubi-Vuillaume</name></author><author><name sortKey="Zahr, Noel" sort="Zahr, Noel" uniqKey="Zahr N" first="Noel" last="Zahr">Noel Zahr</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Poltl, Dominik" sort="Poltl, Dominik" uniqKey="Poltl D" first="Dominik" last="Pöltl">Dominik Pöltl</name></author><author><name sortKey="Leist, Marcel" sort="Leist, Marcel" uniqKey="Leist M" first="Marcel" last="Leist">Marcel Leist</name></author><author><name sortKey="Rose, Christian" sort="Rose, Christian" uniqKey="Rose C" first="Christian" last="Rose">Christian Rose</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name></author><author><name sortKey="Marchetti, Philippe" sort="Marchetti, Philippe" uniqKey="Marchetti P" first="Philippe" last="Marchetti">Philippe Marchetti</name></author><author><name sortKey="Cabantchik, Z Ioav" sort="Cabantchik, Z Ioav" uniqKey="Cabantchik Z" first="Z Ioav" last="Cabantchik">Z Ioav Cabantchik</name></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Régis" last="Bordet">Régis Bordet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24251381</idno><idno type="pmid">24251381</idno><idno type="doi">10.1089/ars.2013.5593</idno><idno type="wicri:Area/PubMed/Corpus">000535</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000535</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting chelatable iron as a therapeutic modality in Parkinson's disease.</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation><nlm:affiliation>1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University , CHU Lille, Lille, France .</nlm:affiliation></affiliation></author><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name></author><author><name sortKey="Devedjian, Jean Christophe" sort="Devedjian, Jean Christophe" uniqKey="Devedjian J" first="Jean Christophe" last="Devedjian">Jean Christophe Devedjian</name></author><author><name sortKey="Kluza, Jerome" sort="Kluza, Jerome" uniqKey="Kluza J" first="Jérome" last="Kluza">Jérome Kluza</name></author><author><name sortKey="Petrault, Maud" sort="Petrault, Maud" uniqKey="Petrault M" first="Maud" last="Petrault">Maud Petrault</name></author><author><name sortKey="Laloux, Charlotte" sort="Laloux, Charlotte" uniqKey="Laloux C" first="Charlotte" last="Laloux">Charlotte Laloux</name></author><author><name sortKey="Jonneaux, Aurelie" sort="Jonneaux, Aurelie" uniqKey="Jonneaux A" first="Aurélie" last="Jonneaux">Aurélie Jonneaux</name></author><author><name sortKey="Ryckewaert, Gilles" sort="Ryckewaert, Gilles" uniqKey="Ryckewaert G" first="Gilles" last="Ryckewaert">Gilles Ryckewaert</name></author><author><name sortKey="Garcon, Guillaume" sort="Garcon, Guillaume" uniqKey="Garcon G" first="Guillaume" last="Garçon">Guillaume Garçon</name></author><author><name sortKey="Rouaix, Nathalie" sort="Rouaix, Nathalie" uniqKey="Rouaix N" first="Nathalie" last="Rouaix">Nathalie Rouaix</name></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name></author><author><name sortKey="Jissendi, Patrice" sort="Jissendi, Patrice" uniqKey="Jissendi P" first="Patrice" last="Jissendi">Patrice Jissendi</name></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Auger, Florent" sort="Auger, Florent" uniqKey="Auger F" first="Florent" last="Auger">Florent Auger</name></author><author><name sortKey="Ravasi, Laura" sort="Ravasi, Laura" uniqKey="Ravasi L" first="Laura" last="Ravasi">Laura Ravasi</name></author><author><name sortKey="Hopes, Lucie" sort="Hopes, Lucie" uniqKey="Hopes L" first="Lucie" last="Hopes">Lucie Hopes</name></author><author><name sortKey="Grolez, Guillaume" sort="Grolez, Guillaume" uniqKey="Grolez G" first="Guillaume" last="Grolez">Guillaume Grolez</name></author><author><name sortKey="Firdaus, Wance" sort="Firdaus, Wance" uniqKey="Firdaus W" first="Wance" last="Firdaus">Wance Firdaus</name></author><author><name sortKey="Sablonniere, Bernard" sort="Sablonniere, Bernard" uniqKey="Sablonniere B" first="Bernard" last="Sablonnière">Bernard Sablonnière</name></author><author><name sortKey="Strubi Vuillaume, Isabelle" sort="Strubi Vuillaume, Isabelle" uniqKey="Strubi Vuillaume I" first="Isabelle" last="Strubi-Vuillaume">Isabelle Strubi-Vuillaume</name></author><author><name sortKey="Zahr, Noel" sort="Zahr, Noel" uniqKey="Zahr N" first="Noel" last="Zahr">Noel Zahr</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Poltl, Dominik" sort="Poltl, Dominik" uniqKey="Poltl D" first="Dominik" last="Pöltl">Dominik Pöltl</name></author><author><name sortKey="Leist, Marcel" sort="Leist, Marcel" uniqKey="Leist M" first="Marcel" last="Leist">Marcel Leist</name></author><author><name sortKey="Rose, Christian" sort="Rose, Christian" uniqKey="Rose C" first="Christian" last="Rose">Christian Rose</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name></author><author><name sortKey="Marchetti, Philippe" sort="Marchetti, Philippe" uniqKey="Marchetti P" first="Philippe" last="Marchetti">Philippe Marchetti</name></author><author><name sortKey="Cabantchik, Z Ioav" sort="Cabantchik, Z Ioav" uniqKey="Cabantchik Z" first="Z Ioav" last="Cabantchik">Z Ioav Cabantchik</name></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Régis" last="Bordet">Régis Bordet</name></author></analytic><series><title level="j">Antioxidants & redox signaling</title><idno type="eISSN">1557-7716</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Combined Modality Therapy</term><term>Disease Models, Animal</term><term>Double-Blind Method</term><term>Humans</term><term>Iron (metabolism)</term><term>Iron Chelating Agents (administration & dosage)</term><term>Iron Chelating Agents (therapeutic use)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Motor Activity (drug effects)</term><term>Oxidative Stress (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Pilot Projects</term><term>Pyridones (administration & dosage)</term><term>Pyridones (pharmacology)</term><term>Pyridones (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Iron Chelating Agents</term><term>Pyridones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Iron</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Pyridones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Iron Chelating Agents</term><term>Pyridones</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term><term>Oxidative Stress</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Combined Modality Therapy</term><term>Disease Models, Animal</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Pilot Projects</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24251381</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>17</Day></DateCreated><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-7716</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Antioxidants & redox signaling</Title><ISOAbbreviation>Antioxid. Redox Signal.</ISOAbbreviation></Journal><ArticleTitle>Targeting chelatable iron as a therapeutic modality in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>195-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/ars.2013.5593</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a delayed-start (DS) treatment paradigm, the basis for preliminary clinical assessments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For translational studies, we assessed the effect of oxidative insults in mice systemically prechelated with deferiprone (DFP) by following motor functions, striatal dopamine (HPLC and MRI-PET), and brain iron deposition (relaxation-R2*-MRI) aided by spectroscopic measurements of neuronal labile iron (with fluorescence-sensitive iron sensors) and oxidative damage by markers of protein, lipid, and DNA modification. DFP significantly reduced labile iron and biological damage in oxidation-stressed cells and animals, improving motor functions while raising striatal dopamine. For a pilot, double-blind, placebo-controlled randomized clinical trial, early-stage Parkinson's patients on stabilized dopamine regimens enrolled in a 12-month single-center study with DFP (30 mg/kg/day). Based on a 6-month DS paradigm, early-start patients (n=19) compared to DS patients (n=18) (37/40 completed) responded significantly earlier and sustainably to treatment in both substantia nigra iron deposits (R2* MRI) and Unified Parkinson's Disease Rating Scale motor indicators of disease progression (p<0.03 and p<0.04, respectively). Apart from three rapidly resolved neutropenia cases, safety was maintained throughout the trial.</AbstractText><AbstractText Label="INNOVATION" NlmCategory="METHODS">A moderate iron chelation regimen that avoids changes in systemic iron levels may constitute a novel therapeutic modality for PD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-modifying potential of chelation in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University , CHU Lille, Lille, France .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Devedjian</LastName><ForeName>Jean Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Kluza</LastName><ForeName>Jérome</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Petrault</LastName><ForeName>Maud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Laloux</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jonneaux</LastName><ForeName>Aurélie</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ryckewaert</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Garçon</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rouaix</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Duhamel</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jissendi</LastName><ForeName>Patrice</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Auger</LastName><ForeName>Florent</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ravasi</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hopes</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Grolez</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Firdaus</LastName><ForeName>Wance</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Sablonnière</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Strubi-Vuillaume</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Zahr</LastName><ForeName>Noel</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Pöltl</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Leist</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cabantchik</LastName><ForeName>Z Ioav</ForeName><Initials>ZI</Initials></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>Régis</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00943748</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antioxid Redox Signal</MedlineTA><NlmUniqueID>100888899</NlmUniqueID><ISSNLinking>1523-0864</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007502">Iron Chelating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BTY8KH53L</RegistryNumber><NameOfSubstance UI="C044919">deferiprone</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Toxicol Lett. 2000 Sep 30;117(1-2):25-35</RefSource><PMID Version="1">11033230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anal Biochem. 2002 May 1;304(1):1-18</RefSource><PMID Version="1">11969183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood Cells Mol Dis. 2002 Nov-Dec;29(3):536-47; discussion 548-52</RefSource><PMID Version="1">12547248</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2003 Mar 27;37(6):899-909</RefSource><PMID Version="1">12670420</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2003 Jun;991:189-98</RefSource><PMID Version="1">12846987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2003 Apr;2(4):246-53</RefSource><PMID Version="1">12849213</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Sep 1;102(5):1583-7</RefSource><PMID Version="1">12763939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Methods. 2004 Aug 30;137(2):221-6</RefSource><PMID Version="1">15262064</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2004 Nov;5(11):863-73</RefSource><PMID Version="1">15496864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1987 Nov 21;2(8569):1219-20</RefSource><PMID Version="1">2890848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci Res. 1990 Dec;27(4):595-611</RefSource><PMID Version="1">2079720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1993;8(1):1-12</RefSource><PMID Version="1">8419792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Pharmacol. 1993 Jun 22;45(12):2417-24</RefSource><PMID Version="1">7687131</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bioenerg Biomembr. 1998 Jun;30(3):207-22</RefSource><PMID Version="1">9733088</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biophys J. 1999 Feb;76(2):725-34</RefSource><PMID Version="1">9929477</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>NMR Biomed. 2004 Nov;17(7):427-32</RefSource><PMID Version="1">15526352</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioorg Med Chem. 2005 Feb 1;13(3):773-83</RefSource><PMID Version="1">15653345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Free Radic Biol Med. 2005 Jul 1;39(1):133-42</RefSource><PMID Version="1">15925285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Nov 1;106(9):3242-50</RefSource><PMID Version="1">16020512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2006 Mar;59(3):559-62</RefSource><PMID Version="1">16489611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Toxicol In Vitro. 2006 Jun;20(4):519-28</RefSource><PMID Version="1">16298102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2006 Jun;97(6):1634-58</RefSource><PMID Version="1">16805774</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Hematol. 2007 May;14(3):183-90</RefSource><PMID Version="1">17414205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Total Environ. 2007 May 15;377(2-3):165-72</RefSource><PMID Version="1">17379277</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Physiol Biochem. 2007 Feb;113(1):30-54</RefSource><PMID Version="1">17522983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Jul 1;110(1):401-8</RefSource><PMID Version="1">17379741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Cell Physiol. 2007 Oct;293(4):C1383-94</RefSource><PMID Version="1">17670894</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2008 Jan;9(1):72-81</RefSource><PMID Version="1">17987043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Feb 1;111(3):1690-9</RefSource><PMID Version="1">17975016</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Biochem Cell Biol. 2008;40(3):350-4</RefSource><PMID Version="1">17451993</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Magn Reson Imaging. 2008 Nov;28(5):1061-7</RefSource><PMID Version="1">18972346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2009 Mar;33(3):429-35</RefSource><PMID Version="1">19110057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Sep 24;361(13):1268-78</RefSource><PMID Version="1">19776408</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2009 Oct;23(10):3263-72</RefSource><PMID Version="1">19542204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2009 Oct 16;284(42):29065-76</RefSource><PMID Version="1">19679656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Oct 27;73(17):1381-7</RefSource><PMID Version="1">19858460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Haematol. 2009;122(2-3):155-64</RefSource><PMID Version="1">19907153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Physiol Pharmacol. 2010 Mar;88(3):187-96</RefSource><PMID Version="1">20393584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Alzheimers Dis. 2010;20 Suppl 2:S551-68</RefSource><PMID Version="1">20463401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antioxid Redox Signal. 2010 Sep 15;13(6):919-49</RefSource><PMID Version="1">20095867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2008 Jun 1;105(6):2466-76</RefSource><PMID Version="1">18331585</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Magn Reson Imaging. 2010 Oct;28(8):1210-5</RefSource><PMID Version="1">20392587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antioxid Redox Signal. 2010 Nov 15;13(10):1593-616</RefSource><PMID Version="1">20214491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2010 Nov;133(11):3423-33</RefSource><PMID Version="1">20736190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2010 Dec 2;468(7324):696-700</RefSource><PMID Version="1">21068725</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cerebellum. 2011 Mar;10(1):1-8</RefSource><PMID Version="1">20865357</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2011 Feb;118(2):223-31</RefSource><PMID Version="1">21165659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metallomics. 2011 Mar;3(3):239-49</RefSource><PMID Version="1">21344071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2011 Mar;118(3):473-7</RefSource><PMID Version="1">21161300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 Apr;134(Pt 4):959-68</RefSource><PMID Version="1">21398376</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Chem. 2011;18(12):1832-45</RefSource><PMID Version="1">21466469</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Glia. 2011 Jun;59(6):927-35</RefSource><PMID Version="1">21446040</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2011 May;10(5):415-23</RefSource><PMID Version="1">21482191</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Aug 1;26(9):1627-32</RefSource><PMID Version="1">21618607</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2011 Sep;164(2b):406-18</RefSource><PMID Version="1">21091647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cardiovasc Magn Reson. 2011;13:45</RefSource><PMID Version="1">21910880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antioxid Redox Signal. 2011 Dec 15;15(12):3003-19</RefSource><PMID Version="1">21545274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2011 Nov;96(11):1708-11</RefSource><PMID Version="1">21791473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2011 Dec;119(5):957-71</RefSource><PMID Version="1">21434924</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Pharm Des. 2011;17(31):3374-80</RefSource><PMID Version="1">21902671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jan 26;366(4):348-59</RefSource><PMID Version="1">22276824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thorax. 2012 Mar;67(3):222-8</RefSource><PMID Version="1">22106016</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antioxid Redox Signal. 2012 May 1;16(9):965-73</RefSource><PMID Version="1">22229791</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Res. 2012 May;65(5):514-22</RefSource><PMID Version="1">22391246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2012 Dec;119(12):1523-8</RefSource><PMID Version="1">22875636</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20590-5</RefSource><PMID Version="1">23169664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2013 Jan;124(2):250-61</RefSource><PMID Version="1">23106162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2013 Aug;12(8):747-55</RefSource><PMID Version="1">23726851</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2013 Aug;14(8):551-64</RefSource><PMID Version="1">23820773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2013 Sep;247:45-58</RefSource><PMID Version="1">23531432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 2002 Feb;87(2):1155-8</RefSource><PMID Version="1">11826083</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Med Chem. 2012;19(17):2816-27</RefSource><PMID Version="1">22455586</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007502" MajorTopicYN="N">Iron Chelating Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4060813</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24251381</ArticleId><ArticleId IdType="doi">10.1089/ars.2013.5593</ArticleId><ArticleId IdType="pmc">PMC4060813</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000535 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000535 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24251381
|texte= Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24251381" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |